Lipigon: Expert in Blood Lipid Diseases

Redeye initiates coverage of Lipigon, a biotech company developing Lipisense, a new first-in-class ANGPTL-4-targeting candidate, based on modern, state-of-the-art, antisense technology. We believe Lipisense could reduce blood fat in the several million people suffering from SHTG, a condition of extreme triglyceride blood levels that leaves patients at high risk for pancreatitis—implying potential blockbuster status for the candidate.



Richard Ramanius

Johan Unnerus

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.